- Identify potential liabilities that lead to manufacturing challenges
- Identify MHC Class II binding epitopes that could lead to immunogenicity
In silico identiﬁcation of sequence liabilities
Many physicochemical modiﬁcations can adversely impact the molecular integrity of biological molecules. To avoid having any nasty surprises further down the development pathway, performing a developability assessment can be a useful screen during your discovery process.
At Abzena, we can perform an in silico assessment to identify a number of potential sequence liabilities which, if not addressed, could lead to manufacturing challenges at a later stage. Amongst the liabilities screened for are: N-linked glycosylation, disulphide scrambling via unpaired cysteines, deamidation and oxidation sites. For peace of mind, the presence of any identiﬁed liability sites can be investigated further using our extensive bioanalytical capabilities and, if needed, removed using our comprehensive protein engineering technologies.
As part of the developability assessment, there is also the option to include Abzena’s iTope™ MHC Class II binding prediction analysis, together with our TCED™ (T cell epitope database) to provide an assessment of T cell epitopes. TCED™ and iTope™ are ideal for rapid screening of large numbers of protein sequences to identify potential leads with reduced risk of immunogenicity for further development.
Working with Abzena
Abzena’s discovery services are tailored for each project to ensure that the objectives are met or exceeded. Experienced project teams are assigned to each study focusing on progressing projects through to results in the minimum amount of time. Our clients widely regard us as professional and attentive partners who deliver quality results.
To get more information, a quote or to schedule a teleconference please contact us.